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Abstract
Mixed Candida/bacterial bloodstream infections (BSIs) have been reported to occur in more than 23% of all episodes of candida-
emia. However, the clinical implications of mixed Candida/bacterial BSIs are not well known. We performed a retrospective case-
control study of all consecutive patients with candidaemia over a 5-year period to determine the risk factors for and clinical
outcomes of mixed Candida/bacterial BSIs (cases) compared with monomicrobial candidaemia (controls). Thirty-seven (29%) out of
126 patients with candidaemia met the criteria for cases. Coagulase-negative staphylococci were the predominant bacteria (23%) in
cases. In multivariate analysis, duration of previous hospital stay ‡7 weeks (odds ratio (OR), 2.86; 95% conﬁdence interval (CI),
1.09–7.53), prior antibiotic therapy ‡7 days (OR, 0.33; 95% CI, 0.14–0.82) and septic shock at the time of candidaemia (OR, 2.60;
95% CI, 1.14–5.93) were signiﬁcantly associated with cases. Documented clearance of candidaemia within 3 days after initiation of
antifungal therapy was less frequent in cases (63% vs. 84%; p = 0.035). The difference in the rate of treatment failure at 2 weeks
was not signiﬁcant between cases (68%) and controls (62%; p = 0.55). The crude mortality at 6 weeks and survival through
100 days did not differ between the two patient groups (p = 0.56 and p = 0.80, respectively). Mixed Candida/bacterial BSIs showed
a lower clearance rate of candidaemia during the early period of antifungal therapy, although the treatment response and survival
rate were similar regardless of concurrent bacteraemia. Further studies on the clinical relevance of species-speciﬁc Candida-bacterial
interactions are needed.
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Introduction
Candida species are normal commensals of humans that com-
monly inhabit the gastrointestinal tract, the female genital tract
and the skin, where diverse bacteria are most commonly
found. Candida and bacteria directly and indirectly inﬂuence
each other in many ways and can have important effects on
each other’s survival, colonization and pathogenesis [1–3].
Although data on the clinical relevance of interactions between
Candida and bacteria are still lacking, several studies have
described associations between this genus of fungus and bacte-
ria species in clinical specimens [4–6]. Previous studies have
demonstrated both synergistic and antagonistic interactions
between Candida and various bacteria species, including Pseu-
domonas aeroginosa, Staphylococcus aureus and Acinetobacter
baumannii [7–11].
With the recent advances in medical technology, Candida
species are the most common cause of invasive fungal infec-
tions. The occurrence of invasive candidiasis has increased
over the past several decades, especially in immunocompro-
mised or critically ill patients, and may contribute to high
mortality and morbidity [12,13]. In most cases of candida-
emia, the gastrointestinal tract and the skin have been con-
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sidered the sources of infection [14]. As mentioned above,
the extensive distribution of bacterial species can lead to
candidaemia with concomitant bacteraemia. Mixed Candida/
bacterial bloodstream infections (BSIs) have been reported
to occur in >23% of all episodes of candidaemia [4]. How-
ever, the mechanisms of Candida-bacterial interaction in
mixed Candida/bacterial BSIs and their clinical importance are
not well known. Furthermore, very few studies have com-
pared the clinical characteristics and outcomes of mixed Can-
dida/bacterial BSIs and monomicrobial candidaemia [4,15].
Therefore, we conducted a retrospective, case-control study




The retrospective, case-control study was conducted at
Korea University Anam Hospital, a 950-bed tertiary care
teaching hospital, located in Seoul, South Korea. There are
three intensive care units (ICUs) of 56 beds. Blood cul-
tures were processed by the automated system Vitek2
(bioMe´rieux, Marcy l’E´toile, France). This study was
approved by the Institutional Review Board of the Korea
University Anam Hospital. Informed consent was not
required by the board because of the retrospective design
of this study.
Study design and deﬁnitions
We identiﬁed all patients aged ‡18 years who had at least
one positive blood culture for Candida species and compati-
ble clinical signs or symptoms from July 2006 to June 2011.
Among these, mixed Candida/bacterial BSI cases were con-
ﬁrmed by isolation of bacterial species growing concomi-
tantly from a single set or different sets of blood cultures
obtained within a 48 h period. We used a standardized deﬁ-
nition of contamination [16]. A blood culture was considered
to be contaminated if one or more of the following organ-
isms were identiﬁed only in one of a series of blood cultures:
coagulase-negative staphylococci, Propionibacterium acnes,
Micrococcus species, viridians group streptococci, Corynebacte-
rium species or Bacillus species.
Medical records were reviewed to determine demo-
graphic data, co-morbidities and other risk factors associated
with Candida infection within 30 days before positive blood
cultures [17]. Neutropenia was deﬁned as an absolute neu-
trophil count of <500 cells/mm3. Deﬁnitions of septic shock
were adapted from the American College of Chest Physi-
cians/Society of Critical Care Medicine Consensus Confer-
ence Committee [18]. Severity of illness at the onset of
candidaemia was assessed using the sequential organ failure
assessment (SOFA) score and the Pitt bacteraemia scoring
system [19,20]. Source of infection was established by clinical
evidence of infection regardless of whether causative organ-
isms were recovered from the affected site. Catheter-related
BSIs were deﬁned according to the Infectious Diseases Soci-
ety of America guidelines [21]. Early central venous catheter
removal meant removing the central venous catheter within
48 h of drawing the ﬁrst blood sample that was culture-posi-
tive for Candida species.
Blood cultures were usually obtained every 3 days until
negative or when clinically indicated. The response to anti-
fungal therapy at 2 weeks was evaluated by the guidelines
for assessing treatment responses and deﬁning study out-
come in clinical trials of invasive fungal diseases published by
the Mycoses Study Group and European Organisation for
Research and Treatment of Cancer as follows: complete and
partial responses were regarded as ‘success’ and stable
response, progression of disease and death were regarded
as ‘failure’ [22]. Candidaemia-attributable mortality was
deﬁned as any of the following: (i) blood cultures positive
for Candida species at the time of death; (ii) death before
the resolution of signs and symptoms related to candida-
emia; or (iii) death at least 14 days after the onset of candi-
daemia without another explanation. The follow-up duration
was 100 days after the ﬁrst date of culture-positive blood
samples for Candida species or until loss to follow-up or
death from any cause. The parameters of mixed Candida/
bacterial BSIs were compared with those of monomicrobial
candidaemia.
Statistical analysis
Continuous variables represented the median and interquar-
tile range (IQR). The chi-squared test or Fisher’s exact test
were used to compare categorical variables, and Student’s
t-test was used to compare continuous variables. Variables
with p-values of < 0.20 by univariate analysis were entered
into the multivariable model. Multivariate analysis was per-
formed by logistic regression analysis for the risk factors
associated with mixed Candida/bacterial BSIs and Cox regres-
sion analysis for the predictive factors for mortality. Kaplan–
Meier survival estimates were used to generate the survival
curves and differences between survival curves were
assessed by means of the log-rank test. Two-sided p-values
of < 0.05 were considered statistically signiﬁcant. Statistical
analysis was performed using SPSS ver. 15.0 (SPSS Korea,
Seoul, Korea).
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Results
Patient characteristics
During a 5-year study period, we identiﬁed a total of 126
patients who had episodes of signiﬁcant candidaemia in our
institution. The overall incidence of candidaemia was 6.6
cases per 10 000 hospital admissions. The most commonly
isolated Candida species was Candida albicans (41% of
isolates), followed by Candida tropicalis (21%), Candida parapsi-
losis (20%) and Candida glabrata (11%). In no case was more
than one Candida species isolated. Out of 126 patients, 37
(29%) showed mixed Candida/bacterial BSIs. The characteris-
tics of the patients and the course of therapy in case and
control patients are shown in Table 1. The two groups did
not differ signiﬁcantly in demographic characteristics, co-
morbidities, risk factors for Candida infection or severity of
illness. With regard to the source of candidaemia and anti-
fungal therapy, there was no signiﬁcant difference. The distri-
bution of Candida species was similar in the two groups
(Fig. 1).
Various bacterial organisms, a total of 44 isolates, were iso-
lated from 37 patients (Fig. 2). Five patients had two and one
patient had three bacterial species isolated. Gram-positive
organisms accounted for more than 68% (30/44) of all bacte-
rial isolates. Coagulase-negative staphylococci (23%, 10/44)
were the most prevalent bacterial pathogen. The central
venous catheter (30%, 11/37) and the gastrointestinal tract
(30%, 11/37) were the most common sources of bacteraemia,
followed by the lower respiratory tract (19%, 7/37), unknown
sources (16%, 6/37) and the urinary tract (5%, 2/37). Appro-
TABLE 1. Demographic and clinical characteristics of the
patients with mixed Candida/bacterial bloodstream infec-






(n = 89) p
Age, median years (IQR) 63 (57–73) 68 (57–74) 0.15
Male sex 19 (51) 54 (61) 0.43
Co-morbidities
Diabetes mellitus 10 (27) 24 (27) 1.00
Chronic kidney disease 6 (16) 10 (11) 0.56
Chronic liver disease 3 (8) 7 (8) 1.00
Solid tumour 17 (46) 43 (48) 0.85
Haematological disease 7 (19) 13 (15) 0.60
Charlson co-morbidity index,
median (IQR)
2 (2–5.5) 2 (1–6) 0.78
Prior hospital stay, median days (IQR) 25 (11–60) 23 (11–38) 0.10
Risk factors for Candida infectiona
ICU residence 19 (51) 32 (36) 0.12
Candida colonization 7 (19) 13 (15) 0.60
Neutropenia 5 (14) 14 (16) 0.79
Chemotherapy 11 (30) 24 (27) 0.83
Corticosteroidb 12 (32) 15 (17) 0.06
Surgery 9 (24) 20 (23) 1.00
Hyperalimentation 29 (78) 79 (89) 0.16
Central venous catheter 30 (81) 65 (73) 0.38
Urinary catheter 26 (70) 56 (63) 0.54
Prior use of antibiotics 33 (89) 83 (93) 0.48
Prior azole exposure 5 (14) 11 (12) 1.00
Severity of illness
SOFA score, median (IQR) 7 (3–10) 6 (2.5–9) 0.13
Pitt bacteraemia score,
median (IQR)
4 (2–7.5) 3 (1–6) 0.14
Source of candidaemia
Catheter 10 (27) 26 (29) 0.49
Gastrointestinal tract 13 (35) 41 (46)
Othersc 3 (8) 4 (5)
Unknown 11 (30) 18 (20)
First-line antifungal agent
Fluconazole 18 (49) 45 (51) 0.63
Amphotericin B 9 (24) 15 (17)
Othersd 2 (5) 3 (3)
None 8 (22) 26 (29)
Delay in initiation of antifungal
therapy, median days (IQR)e
3 (1–4) 2 (1–3) 0.53
Total antifungal therapy,
median days (IQR)
22 (7–27) 14 (7–21) 0.80
Data are no. (%) of patients, unless otherwise indicated.
ICU, intensive care unit; IQR, interquartile range; SOFA, sequential organ failure
assessment.
aRisk factors within 30 days before candidaemia.
bA mean minimum dose of 10 mg/day of prednisone equivalent for >14 days.
cGenitourinary tract (n = 6) and deep soft tissue (n = 1).
dItraconazole (n = 4) and caspofungin (n = 1).
eThe time between drawing the ﬁrst blood samples culture-positive for Candida
species and initiation of antifungal therapy.
FIG. 1. Comparison of the distribution of Candida species isolated
from cases and controls. *Citrobacter famata (n = 2), Citrobacter guil-
liermondii (n = 2), Citrobacter ciferrii (n = 1), Citrobacter krusei (n = 1),
Citrobacter lusitaniae (n = 1) and Citrobacter sphaerica (n = 1).
FIG. 2. Distribution of the bacterial species isolated from 37 cases.
CNS, coagulase-negative staphylococci. *Leuconostoc pseudomesentero-
ides (n = 1) and Gram-positive bacillus (n = 1). Citrobacter freundii
(n = 1) and Brevundimonas vesicularis (n = 1).
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priate antibiotics were administered to all cases except three
(one for methicillin-resistant coagulase-negative staphylococ-
cus and two for multidrug-resistant Acinetobacter baumannii).
Appropriate antibiotic therapy was started on a median of
1 day (IQR, 0–11 days) after the onset of bacteraemia.
Risk factors for mixed Candida/bacterial BSIs
In univariate analysis, cases tended to have had a previous
hospital stay of ‡7 weeks (30% vs. 16%; p = 0.08) and to
have received corticosteroids prior to the onset of candida-
emia, compared with controls (32% vs. 17%; p = 0.06). Prior
antibiotic use for ‡7 days was associated with a lower
chance of having mixed Candida/bacterial BSIs (62% vs. 80%;
p = 0.04). Cases more commonly manifested as septic shock
at the time of candidaemia (51% vs. 32%; p = 0.04). Table 2
shows the results of univariate and multivariate analyses of
risk factors for mixed Candida/bacterial BSIs. After multivari-
ate analysis, previous hospital stay for ‡7 weeks, prior antibi-
otic use for ‡7 days and the presence of septic shock at the
time of candidaemia were signiﬁcantly associated with mixed
Candida/bacterial BSIs.
Clinical outcome of mixed Candida/bacterial BSIs
The clinical outcomes of cases and controls are shown in
Table 3. Within 3 days after initiation of antifungal therapy,
documented clearance of candidaemia was signiﬁcantly infre-
quent in cases (p = 0.035; Table 3). After adjustment for the
ﬁrst-line antifungal agent, ‡48 h delay in initiation of antifun-
gal therapy and early removal of central venous catheter by
multivariate analysis, mixed Candida/bacterial BSI was only a
signiﬁcant factor associated with clearance of candidaemia at
day 3 (OR, 0.26; 98% CI, 0.08–0.84; p = 0.024). For the
treatment response at 2 weeks, 25 of 37 (68%) cases and 55
of 89 (62%) controls had a treatment failure (p = 0.55). Of
the reasons for treatment failure, microbiological failure was
observed for 14% of cases and 6% of controls (p = 0.16). In
subgroup analysis according to Candida and bacterial species,
there were no signiﬁcant differences in the documented
clearance of candidaemia within 3 days or treatment
response at 2 weeks (data not shown).
Overall mortality at 6 weeks was 59% (74/126) of all
candidaemic patients. Thirty-four (27%) patients did not
receive any antifungal therapy; of these, 28 (82%) died at
week 6. Differences between cases and controls were not
signiﬁcant in the crude and candidaemia-attributable mortal-
ity at 6 weeks (p = 0.43 and p = 1.00, respectively;
Table 3). In univariate analysis, mixed Candida/bacterial BSI
was not predictive of crude mortality at 6 weeks
(p = 0.72). Predictive factors of the 6-week mortality are
shown in Table 4. After multivariate analysis, a Charlson
co-morbidity index ‡4, surgery, SOFA score ‡10, Pitt bac-
teraemia score ‡8, delay in initiation of antifungal therapy
>72 h and persistent candidaemia at the last blood culture
remained independent predictors for crude mortality at
6 weeks. Kaplan–Meier estimates of survival are shown in
Fig. 3. The median time to death was 45 days in cases and
40 days in controls (p = 0.89).
TABLE 2. Logistic regression analy-
sis for risk factors associated with
mixed Candida/bacterial blood-
stream infections
Characteristics OR (95% CI) p
Adjusted OR
(95% CI) p
Duration of previous hospital stay ‡7 weeks 2.27 (0.92–5.61) 0.08 2.86 (1.09–7.53) 0.033
ICU residence 1.88 (0.87–4.09) 0.11 – 0.24
Corticosteroida 2.37 (0.98–5.73) 0.06 – 0.10
Hyperalimentationa 0.46 (0.17–1.28) 0.14 – 0.16
Duration of prior antibiotic therapy ‡7 daysa 0.42 (0.18–0.97) 0.04 0.33 (0.14–0.82) 0.016
Septic shock 2.30 (1.05–5.04) 0.04 2.60 (1.14–5.93) 0.024
SOFA score ‡10 1.87 (0.81–4.32) 0.14 – 0.42
Pitt bacteraemia score ‡8 2.06 (0.79–5.42) 0.14 – 0.41
ICU, intensive care unit; OR, odds ratio; SOFA, sequential organ failure assessment.
aRisk factors within 30 days before candidaemia.
TABLE 3. Comparison of clinical outcomes between
patients with mixed Candida/bacterial bloodstream infec-






(n = 89) p
Documented clearance of
candidaemia within 3 days
after initiation of antifungal
therapya
19/30 (63) 48/57 (84) 0.035
Treatment failure at 2 weeks 25 (68) 55 (62) 0.55
Clinical failureb 5 (14) 13 (15) 1.00
Microbiological failurec 5 (14) 5 (6) 0.16
Death 15 (41) 37 (42) 1.00
Mortality at 6 weeks
Crude 24 (65) 50 (56) 0.43
Candidaemia-attributable 16 (43) 37 (42) 1.00
Data are no. (%) of patients, unless otherwise indicated.
aData are event/evaluable no. (%) of patients.
bWorsening or no improvement of attributable symptoms or signs of candida-
emia.
cPersistent isolation of Candida species from blood specimens at 2 weeks.
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Discussion
In this study, a signiﬁcant portion of candidaemia episodes
occurred concurrently with bacteraemia. Compared with mo-
nomicrobial candidaemia, mixed Candida/bacterial BSIs were
associated with a prolonged length of previous hospital stay
(‡7 weeks) and septic shock at the time of candidaemia. Prior
receipt of antibiotic agents for ‡7 days was related to mono-
microbial candidaemia rather than mixed Candida/bacterial
BSIs. We found that documented clearance of candidaemia
during the early period of antifungal therapy was deferred in
patients with concurrent bacteraemia. However, treatment
responses at 2 and 6 weeks and survival through 100 days
were not signiﬁcantly different between mixed Candida/bacte-
rial BSIs and monomicrobial candidaemia.
Mixed Candida/bacterial BSIs have been commented in sev-
eral articles on candidaemia, the results of which have sug-
gested that the incidence of concurrent bacteraemia
accounts for 23% of all episodes of candidaemia [4,23].
Thorn et al. [24] reported that 39% of the post-mortem
blood cultures with Candida species were polymicrobial. We
observed a similar incidence in previous studies. However,
the concept of ‘polymicrobial BSI’ or ‘concomitant BSI’ was
not properly identiﬁed in most previous articles and an ofﬁ-
cial deﬁnition has still not been established. The following
deﬁnition has mainly been used: the isolation of bacterial
species synchronously with Candida species or within 48 h of
the time of candidaemia. Previous studies have reported the
incidence of concurrent bacteraemia to be 7–27%. Abi-Said
et al. [25] showed that concomitant bacterial infection
deﬁned as isolation of bacteria 1 week prior to or after the
time of candidaemia occurred in 57% of patients. In this
study, we used the term ‘mixed Candida/bacterial BSI’ to
describe the isolation of bacterial species within 48 h of the
time of candidaemia to avoid confusion with previous stud-
ies. We chose this deﬁnition because concomitant bactera-
emia may obscure the detection of fungaemia using standard
blood culture techniques by suppression of fungal growth
[9,10,26]. The inclusion of only synchronous candidaemia and
bacteraemia could cause the underestimation of the inci-
dence of mixed Candida/bacterial BSIs.
TABLE 4. Predictors of the 6-week
mortality in all candidaemic
patients
Characteristics HR (95% CI) p
Adjusted HR
(95% CI) p
Mixed Candida/bacterial BSI 1.09 (0.67–1.78) 0.72 – ND
Gram-positive bacteria 0.76 (0.42–1.39) 0.37 – ND
Gram-negative bacteria 1.67 (0.86–3.25) 0.13 – 0.15
Co-morbidities
Chronic kidney disease 2.03 (1.11–3.72) 0.021 – 0.96
Charlson co-morbidity index ‡4 1.79 (1.13–2.85) 0.014 1.91 (1.17–3.13) 0.01
Risk factors for Candida infectiona
ICU residence 1.77 (1.12–2.80) 0.015 – 0.36
Neutropenia 1.46 (0.82–2.62) 0.20 – 0.08
Chemotherapy 1.56 (0.95–2.54) 0.08 – 0.15
Corticosteroids 1.59 (0.94–2.68) 0.09 – 0.27
Surgery 0.46 (0.24–0.88) 0.02 0.34 (0.17–0.65) 0.001
Hyperalimentation 1.72 (0.83–3.60) 0.15 - 0.31
Severity of illness
SOFA score ‡10 3.78 (2.33–6.12) <0.001 3.00 (1.73–5.18) <0.001
Pitt bacteraemia score ‡8 4.83 (2.80–8.33) <0.001 6.98 (3.32–14.70) <0.001
Mechanical ventilation 1.90 (1.19–3.02) 0.007 – 0.76
Continuous renal replacement therapy 1.90 (1.02–3.54) 0.04 – 0.07
Delay in initiation of antifungal therapy >72 h 1.87 (1.16–3.00) 0.01 2.03 (1.23–3.35) 0.006
Early central venous catheter removal 0.68 (0.41–1.13) 0.13 – 0.99
Persistent candidaemia at the last blood culture 5.87 (3.62–9.52) <0.001 7.60 (4.36–13.25) <0.001
BSI, bloodstream infection; HR, hazard ratio; ICU, intensive care unit; SOFA, sequential organ failure assessment.
aRisk factors within 30 days prior to candidaemia.
FIG. 3. Kaplan–Meier estimates of survival in patients with mixed
Candida/bacterial bloodstream infection and monomicrobial candida-
emia.
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We found that clearance of candidaemia within 3 days
after the start of antifungal therapy was signiﬁcantly infre-
quent in mixed Candida/bacterial BSIs, compared with mono-
microbial candidaemia. This result might be explained by the
following mechanisms: the synergistic relationship between
Candida and bacteria species enhances the viability of Candida
[27,28], and/or fungal growth is increased by antibacterial
treatment for co-infected bacteria with an antagonistic effect
on Candida species [10,29]. However, the clinical signiﬁcance
of synergism between Candida and bacteria species has not
been proven, and quantitative blood culture was not per-
formed in this study. Further in vitro and in vivo investigations
are needed to test this hypothesis.
It is not yet clear whether mixed-species infections have
different clinical outcomes than single-species infections. Sev-
eral studies have reported signiﬁcant implications of Candida-
bacterial interactions in animal models and various clinical
settings, including bioﬁlms on implanted medical devices,
peritonitis and ventilator-associated pneumonia [6,8,30,31].
As far as we know, only one study has compared clinical
outcomes in BSIs by mixed Candida-bacteria species and Can-
dida species alone. Dyess et al. [15] reported a poorer clini-
cal outcome in patients with synchronous candidaemia and
bacteraemia (39% survival) than in patients with only candi-
daemia (67% survival; p < 0.05). However, they did not pres-
ent the demographic characteristics, underlying disease and
severity of illness in each patient group. Unlike their result,
our study showed no difference in clinical outcome between
mixed Candida/bacterial BSIs and monomicrobial candidaemia.
Concomitant bacteraemia was also not a predictive factor of
the 6-week mortality. Mortality at 6 weeks was associated
with the Charlson co-morbidity index, SOFA score, Pitt bac-
teraemia score, recent surgery, delayed start of antifungal
therapy and persistent candidaemia. These ﬁndings suggest
that chronic co-morbid conditions and severity of illness at
the onset of candidaemia are the key factors of clinical out-
come of candidaemic patients.
This study has several limitations. Because we performed
a retrospective analysis with single-centre data, the distribu-
tion of the causative pathogens (both Candida and bacteria
species) in our institution could have had an impact on the
results. Also, a relatively small number of cases caused by
each bacterial species was included and we did not analyse
the clinical inﬂuence of mixed Candida/bacterial BSIs accord-
ing to the bacterial species. However, to the best of our
knowledge, this is the ﬁrst report on the risk factors for and
clinical outcomes of mixed Candida/bacterial BSIs compared
with monomicrobial candidaemia. Our results suggest that
empirical antibacterial and antifungal therapy should be prop-
erly considered on the basis of local microbiological epidemi-
ology and susceptibility proﬁles in cases with risk factors for
mixed Candida/bacterial BSIs. Although mixed Candida/bacte-
rial BSIs are not predictive for a poor prognosis with appro-
priate antimicrobial therapy, more aggressive policies to
clear Candida species from blood might be required in the
early period of antimicrobial therapy to minimize the possi-
bility of metastatic complications.
In our study, mixed Candida/bacterial BSIs accounted for a
considerable part of candidaemia. We found several risk fac-
tors for and clinical implications of mixed Candida/bacterial
BSIs. The interactions between Candida and bacteria species
are highly complex and their clinical impact could be inﬂu-
enced by host factors, microbial pathogen and antimicrobial
therapy. To understand the mechanisms of Candida-bacterial
interactions in the bloodstream and exploit it for therapeutic
strategies, further studies using in vitro or animal model sys-
tems as well as large-scale, multicentre clinical data are
needed.
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